Skip to main navigation Skip to search Skip to main content

Standard vs. Targeted Oxygen Therapy Prehospitally for Chronic Obstructive Pulmonary Disease (STOP-COPD); study protocol for a randomized controlled trial

  • Arne Sylvester Rønde Jensen*
  • , Jan Brink Valentin
  • , Mathilde Gundgaard Mulvad
  • , Victor Hagenau
  • , Søren Helbo Skaarup
  • , Søren Paaske Johnsen
  • , Ulla Væggemose
  • , Martin Faurholdt Gude
  • *Corresponding author for this work

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Abstract

BACKGROUND: A high concentration of inspired supplemental oxygen may possibly cause hypercapnia and acidosis and increase mortality in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Even so, patients with AECOPD are being treated with high oxygen flow rates when receiving inhalation drugs in the prehospital setting. A cluster-randomised controlled trial found that reduced oxygen delivery by titrated treatment reduced mortality-a result supported by observational studies-but the results have never been reproduced. In the STOP-COPD trial, we investigate the effect of titrated oxygen delivery compared with usual care consisting of high flow oxygen delivery in patients with AECOPD in the prehospital setting.

METHODS: In this randomised controlled trial, patients will be blinded to allocation. Patients with suspected AECOPD (n = 1888) attended by the emergency medical service (EMS) and aged > 40 years will be allocated randomly to either standard treatment or titrated oxygen, targeting a blood oxygen saturation of 88-92% during inhalation therapy. The trial will be conducted in the Central Denmark Region and include all ambulance units. The power to detect a 3% 30-day mortality risk difference is 80%. The trial is approved as an emergency trial. Hence, EMS providers will include patients without prior consent.

DISCUSSION: The results will provide evidence on whether titrated oxygen delivery outperforms standard high flow oxygen when used to nebulise inhaled bronchodilators in AECOPD treatment. The trial is designed to ensure unselected inclusion of patients with AECOPD needing nebulised bronchodilators-a group of patients that receives high oxygen fractions when treated in the prehospital setting where the only compressed gas is generally pure oxygen. Conducting this trial, we aim to improve treatment for people with AECOPD while reducing their 30-day mortality.

TRIAL REGISTRATION: European Union Clinical Trials (EUCT) number: 2022-502003-30-00 (authorised 06/12/2022), ClinicalTrials.gov number: NCT05703919 (released 02/02/2023), Universal trial number: U1111-1278-2162.

Original languageEnglish
JournalDansk Tidsskrift for Akutmedicin
Volume7
Issue number1
Pages (from-to)44-44
Number of pages1
Publication statusPublished - Feb 2024
EventDanish Emergency Medicine Conference: DCEM 10 - Comfort Hotel & Congress Copenhagen Airport, København, Denmark
Duration: 2 Nov 2023 → 3 Nov 2023
Conference number: 10
https://www.meetingplanners.dk/subsites/demc/index.html

Conference

ConferenceDanish Emergency Medicine Conference
Number10
LocationComfort Hotel & Congress Copenhagen Airport
Country/TerritoryDenmark
CityKøbenhavn
Period02/11/2023 → 03/11/2023
Internet address

Bibliographical note

© 2024. The Author(s).

Keywords

  • Adult
  • Aged
  • Bronchodilator Agents/therapeutic use
  • Humans
  • Hypercapnia/etiology
  • Middle Aged
  • Oxygen Inhalation Therapy/adverse effects
  • Oxygen/therapeutic use
  • Pulmonary Disease, Chronic Obstructive/therapy
  • Randomized Controlled Trials as Topic

Fingerprint

Dive into the research topics of 'Standard vs. Targeted Oxygen Therapy Prehospitally for Chronic Obstructive Pulmonary Disease (STOP-COPD); study protocol for a randomized controlled trial'. Together they form a unique fingerprint.

Cite this